Publicacións en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (5)

2023

  1. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 24, Núm. 12, pp. 1399-1410

2022

  1. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

    The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 2, pp. 118-127

2021

  1. Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways

    Advances in Therapy

2018

  1. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease

    Gastroenterology, Vol. 154, Núm. 5, pp. 1334-1342.e4

2016

  1. Ustekinumab as induction and maintenance therapy for Crohn's disease

    New England Journal of Medicine, Vol. 375, Núm. 20, pp. 1946-1960